Skip to main content
. 2023 Feb 16;28:249–263. doi: 10.1016/j.omto.2023.02.004

Figure 7.

Figure 7

EGFRvIII+/HER2+ heterogeneous model of GBM

(A) T cell-mediated cytotoxicity assay against U87vIII cells (EGFRvIII+) and/or U251 cells (HER2+) using NSG mice treated with EGFRvIII-DBTE and/or HER2-DBTE. (B) Fluorescent images of the heterogeneous tumor mixture (U87vIII/U251) in a 48-h tumor-killing assay.